Salud financiera de hoja de balance de Fusen Pharmaceutical

Salud financiera controles de criterios 1/6

Fusen Pharmaceutical tiene un patrimonio de accionistas total de CN¥562.2M y una deuda total de CN¥342.3M, lo que sitúa su ratio deuda-patrimonio en 60.9%. Sus activos y pasivos totales son CN¥1.3B y CN¥781.5M respectivamente. El BAIT de Fusen Pharmaceutical es de CN¥21.5M, por lo que su ratio de cobertura de intereses es de 2.4. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥34.8M.

Información clave

61.7%

Ratio deuda-patrimonio

CN¥346.86m

Deuda

Ratio de cobertura de intereses	1.8x
Efectivo	CN¥34.85m
Patrimonio	CN¥562.23m
Total pasivo	CN¥781.52m
Activos totales	CN¥1.34b

Actualizaciones recientes sobre salud financiera

Recent updates

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Dec 14

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Sep 02

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Apr 02

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

Mar 06

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥566.8M) de 1652 no cubren sus pasivos a corto plazo (CN¥664.5M).

Pasivo a largo plazo: Los activos a corto plazo de 1652 (CN¥566.8M) superan a sus pasivos a largo plazo (CN¥117.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 1652 (54.7%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 1652 ha crecido de 30.8% a 60.9% en los últimos 5 años.

Cobertura de la deuda: El flujo de caja operativo de 1652 es negativo, por lo que la deuda no está bien cubierta.

Cobertura de intereses: Los pagos de intereses de la deuda de 1652 no están bien cubiertos por el BAIT (2.4x cobertura).

Salud financiera de hoja de balance de Fusen Pharmaceutical

Salud financiera controles de criterios 1/6

Información clave

Actualizaciones recientes sobre salud financiera

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Recent updates

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Market bids up stock over the past week

New 90-day high: HK$6.00

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Market bids up stock over the past week

New 90-day high: HK$4.69

Market bids up stock over the past week

First half earnings released